Core Perspective - Defence Therapeutics Inc. is evolving its corporate positioning to focus on its proprietary Accum® platform, aimed at enhancing intracellular drug delivery for cancer treatments [1][2][4] Group 1: Company Strategy - The company is prioritizing the Accum® platform through a dual strategy that combines internal R&D programs with strategic partnerships in the biotech and pharmaceutical sectors [3][4] - Accum® is designed to improve cellular uptake and payload release, increasing therapeutic potency at lower doses while potentially reducing toxicity [2][3] Group 2: Commitment to Precision Oncology - Defence Therapeutics aims to transform therapies traditionally used in later lines into safer, more effective first-line treatment options [3] - The company emphasizes collaboration and the translation of cutting-edge science into life-changing treatments, with a business model focused on generating scalable value for partners and long-term value for shareholders [4][5]